Injectable hydrogels for bone and cartilage repair

2012 ◽  
Vol 7 (2) ◽  
pp. 024105 ◽  
Author(s):  
Ashley A Amini ◽  
Lakshmi S Nair
2018 ◽  
Vol 18 (3) ◽  
pp. 154-170 ◽  
Author(s):  
Sofia Bougioukli ◽  
Christopher H. Evans ◽  
Ram K. Alluri ◽  
Steven C. Ghivizzani ◽  
Jay R. Lieberman

2021 ◽  
Author(s):  
Qi Zhang ◽  
Huaxing Xu ◽  
Chu Wu ◽  
Yinghui Shang ◽  
Qing Wu ◽  
...  

Medicine ◽  
2021 ◽  
Vol 100 (1) ◽  
pp. e24107
Author(s):  
Li Bocun ◽  
Li Jing ◽  
Li Jia ◽  
Qian Tan ◽  
Jianyi Chen ◽  
...  

2021 ◽  
pp. 247-258
Author(s):  
Fabio Valerio Sciarretta

2020 ◽  
Vol 15 (9) ◽  
pp. 2129-2142
Author(s):  
Jun Zhang ◽  
Ziming Liu ◽  
Yuwan Li ◽  
Qi You ◽  
Jibin Yang ◽  
...  

Ligament/tendon and cartilage injuries are clinically common diseases that perplex most clinicians. Because of the lack of blood vessels and nerves, their self-repairing abilities are rather poor. Therefore, surgeries are necessary and also widely used to treat ligament/tendon or cartilage injuries. However, after surgery, there are still many problems that affect healing. In recent years, it has been found that exogenous FGF2 plays an important role in the repair of ligament/tendon and cartilage injuries and exerts a synergistic effect with endogenous FGF2. Therefore, FGF2 can be used as a new type of biomolecule to accelerate tendon-to-bone healing and cartilage repair after injury.


2019 ◽  
Vol 48 (11) ◽  
pp. 2839-2849 ◽  
Author(s):  
Seong Hwan Kim ◽  
Yoshi Pratama Djaja ◽  
Yong-Beom Park ◽  
Jung-Gwan Park ◽  
Young-Bong Ko ◽  
...  

Background: Although many clinical studies have assessed the efficacy of mesenchymal stem cells (MSCs) in knee osteoarthritis, evidence on their efficacy remains unclear owing to heterogeneity of cell entity and concomitant procedures. Purpose: To determine the efficacy of culture-expanded MSCs in knee osteoarthritis in terms of clinical outcome and cartilage repair via meta-analysis of randomized controlled trials (RCTs) without adjuvant surgery. Study Design: Meta-analysis. Methods: PubMed, Embase, the Cochrane Library, CINAHL, and Scopus were searched from inception to December 31, 2018. RCTs with culture-expanded MSCs for treating knee osteoarthritis were included. Studies with adjuvant surgery or cell concentrate were excluded. Quality was assessed by the Cochrane Collaboration risk-of-bias tool. For meta-analysis, data on clinical outcomes were measured using a visual analog scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and data on cartilage repair were measured using the Whole-Organ Magnetic Resonance Imaging Score (WORMS); categorization related to improvement was extracted. Results: Six RCTs (203 patients) were included. Two studies were deemed to have a low risk of bias. In pooled analysis, the only significant difference was in the VAS score (mean difference, –13.55; 95% CI, –22.19 to −4.9). In cumulative pain analysis with VAS and WOMAC pain scores, there was significant improvement after treatment (standardized mean difference, –0.54; 95% CI, –0.85 to −0.23). There was no significant difference in cartilage repair assessed by magnetic resonance imaging (standardized mean difference, 0.11; 95% CI, –0.51 to 0.73), WORMS (standardized mean difference, 1.68; 95% CI −14.84 to 18.21), or categorical results (odds ratio, 1.56; 95% CI, 0.32-7.59). Conclusion: Intra-articular injection of culture-expanded MSCs without adjuvant surgery can improve pain for patients experiencing knee osteoarthritis at short-term follow-up (6-12 months). However, evidence regarding function and cartilage repair remains limited.


2017 ◽  
Vol 23 (11) ◽  
pp. 745-753 ◽  
Author(s):  
Christian G. Pfeifer ◽  
Matthew B. Fisher ◽  
Vishal Saxena ◽  
Minwook Kim ◽  
Elizabeth A. Henning ◽  
...  

2019 ◽  
Vol 37 (8) ◽  
pp. 1671-1680 ◽  
Author(s):  
Domhnall C. Kelly ◽  
Rosanne M. Raftery ◽  
Caroline M. Curtin ◽  
Caitriona M. O’Driscoll ◽  
Fergal J. O’Brien

Sign in / Sign up

Export Citation Format

Share Document